drugset / Trial / NCT06337630
A Study on Tuvusertib (Oral ATR Inhibitor) in Combination With PLX038 (Topo1 Inhibitor) in Patients With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
Phase I with a dose finding cohort, followed by expansion cohorts in pre-specified tumor types.
Timeline
- Start
- 2025-01-20
- Primary completion
- 2025-11-24
- Completion
- 2025-11-24
Outcome
Outcome not reported
Stopped: “Although no safety signal has been observed, given that the industrial development of tuvusertib has been halted regardless of the results, we see no scientific and ethical justification for continuing the study”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DFP-13318 | Other / unclassified | 800 mg/m2 | Intravenous |
| Subject | DFP-13318 | Other / unclassified | 1000 mg/m2 | Intravenous |
| Subject | DFP-13318 | Other / unclassified | 1300 mg/m2 | Intravenous |
| Subject | DFP-13318 | Other / unclassified | 1700 mg/m2 | Intravenous |
| Subject | Tuvusertib | Small molecule | 90 mg | Oral |
| Subject | Tuvusertib | Small molecule | 130 mg | Oral |
| Subject | Tuvusertib | Small molecule | 180 mg | Oral |